Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

• Published in: Diabetes, obesity & metabolism Vol. 15; no. 9; pp. 853 - 862
• Main Authors: Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., List, J.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.09.2013; Wiley Subscription Services, Inc; John Wiley & Sons Ltd
• Subjects: Adolescent; Adult; Aged; Antidiabetics; Benzhydryl Compounds; Blindness; Blood Glucose - metabolism; Blood Pressure; Body weight; dapagliflozin; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diuretics; Diuretics - administration & dosage; Diuretics - therapeutic use; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular filtration rate; Glucose; Glucose transporter; Glucosides - administration & dosage; Glucosides - therapeutic use; HbA1c; Hemoglobin; Humans; Hydrochlorothiazide; Hydrochlorothiazide - administration & dosage; Hydrochlorothiazide - therapeutic use; Hyperglycemia; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - therapeutic use; Male; Middle Aged; Original; Placebos; Plasma; Renal function; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; type 2 diabetes; Weight Loss - drug effects; blood pressure; renal function; type 2 diabetes; HbA1c; dapagliflozin

Aims Sodium–glucose co‐transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tubule. Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia in type 2 diabetes by increasing renal glucose excretion. To investigate whether the parallel occurring sodium loss would have diuretic‐li...